Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine.
Aromatase inhibitor
Breast cancer
Estrogen receptor
Letrozole
Monocyte
Stimuvax
Tecemotide
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
25
04
2024
accepted:
09
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
8
10
2024
Statut:
epublish
Résumé
Monocytes comprise subsets of classical, intermediate and non-classical monocytes with distinct anti- or pro-tumor effects in breast cancer (BC). They are modulated by estrogen, and can contribute to BC control by endocrine therapy in preclinical models. To elucidate whether changes in monocyte subsets are associated with treatment and response, we investigated peripheral blood samples of 73 postmenopausal women with estrogen receptor (ER) positive BC, who received aromatase inhibitor therapy with or without the mucin-1 vaccine tecemotide in the ABCSG34 trial. Blood was retrieved at baseline, midterm and end of therapy, and was analyzed for the distribution and ER expression of monocyte subsets by flow cytometry. When 40 healthy, age-matched women were compared with BC patients before treatment start, ER levels of monocytes did not differ, yet patients presented with a higher frequency of classical and fewer non-classical monocytes. Endocrine therapy triggered a significant increase in ER levels in all monocyte subsets, without affecting subset distribution. Vaccination had no overall impact on subset frequency and ER expression. Yet, a shift from intermediate to classical monocytes during therapy correlated with changes in plasma cytokines and chemokines and was significantly associated with low residual cancer burden in vaccinated patients. Without tecemotide, baseline ER levels in classical monocytes were significantly higher in women with good response to endocrine therapy. This study identified classical monocytes to be associated with ER positive BC and with patient response to neoadjuvant endocrine treatment and cancer vaccination.
Sections du résumé
BACKGROUND
BACKGROUND
Monocytes comprise subsets of classical, intermediate and non-classical monocytes with distinct anti- or pro-tumor effects in breast cancer (BC). They are modulated by estrogen, and can contribute to BC control by endocrine therapy in preclinical models.
METHODS
METHODS
To elucidate whether changes in monocyte subsets are associated with treatment and response, we investigated peripheral blood samples of 73 postmenopausal women with estrogen receptor (ER) positive BC, who received aromatase inhibitor therapy with or without the mucin-1 vaccine tecemotide in the ABCSG34 trial. Blood was retrieved at baseline, midterm and end of therapy, and was analyzed for the distribution and ER expression of monocyte subsets by flow cytometry.
RESULTS
RESULTS
When 40 healthy, age-matched women were compared with BC patients before treatment start, ER levels of monocytes did not differ, yet patients presented with a higher frequency of classical and fewer non-classical monocytes. Endocrine therapy triggered a significant increase in ER levels in all monocyte subsets, without affecting subset distribution. Vaccination had no overall impact on subset frequency and ER expression. Yet, a shift from intermediate to classical monocytes during therapy correlated with changes in plasma cytokines and chemokines and was significantly associated with low residual cancer burden in vaccinated patients. Without tecemotide, baseline ER levels in classical monocytes were significantly higher in women with good response to endocrine therapy.
CONCLUSIONS
CONCLUSIONS
This study identified classical monocytes to be associated with ER positive BC and with patient response to neoadjuvant endocrine treatment and cancer vaccination.
Identifiants
pubmed: 39380101
doi: 10.1186/s12967-024-05659-w
pii: 10.1186/s12967-024-05659-w
doi:
Substances chimiques
Aromatase Inhibitors
0
Cancer Vaccines
0
Mucin-1
0
Receptors, Estrogen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
913Subventions
Organisme : Oesterreichische Nationalbank
ID : 15104
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol. 2008;66:65–74.
pubmed: 17949989
doi: 10.1016/j.critrevonc.2007.09.001
Demicheli R, Ardoino I, Boracchi P, Coradini D, Agresti R, Ferraris C, Gennaro M, Hrushesky WJ, Biganzoli E. Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer. 2010;10:656.
pubmed: 21118508
pmcid: 3002930
doi: 10.1186/1471-2407-10-656
Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019;116:135–70.
pubmed: 31036290
pmcid: 6533072
doi: 10.1016/bs.apcsb.2019.01.001
Burstein HJ. Systemic therapy for Estrogen Receptor-Positive, HER2-Negative breast Cancer. N Engl J Med. 2020;383:2557–70.
pubmed: 33369357
doi: 10.1056/NEJMra1307118
Madigan LI, Dinh P, Graham JD. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines. Breast Cancer Res. 2020;22:77.
pubmed: 32690069
pmcid: 7370425
doi: 10.1186/s13058-020-01314-6
Braun DP, Crist KA, Shaheen F, Staren ED, Andrews S, Parker J. Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity. Am J Surg. 2005;190:570–1.
pubmed: 16164922
doi: 10.1016/j.amjsurg.2005.06.013
Degregorio M, Degregorio M, Wurz GT, Wurz GT, Gutierrez A, Gutierrez A, Wolf M. L-BLP25 vaccine plus letrozole for breast cancer: is translation possible? Oncoimmunology. 2012;1:1422–4.
pubmed: 23243615
pmcid: 3518524
doi: 10.4161/onci.21129
Mehta NR, Wurz GT, Burich RA, Greenberg BE, Griffey S, Gutierrez A, Bell KE, McCall JL, Wolf M, DeGregorio M. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice. Clin Cancer Res. 2012;18:2861–71.
pubmed: 22434666
doi: 10.1158/1078-0432.CCR-12-0168
Apostolopoulos V, Stojanovska L, Gargosky SE. MUC1 (CD227): a multi-tasked molecule. Cell Mol Life Sci. 2015;72:4475–500.
pubmed: 26294353
pmcid: 11113675
doi: 10.1007/s00018-015-2014-z
Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, Maeda T, Hu X, Adeegbe D, et al. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene. 2017;36:4037–46.
pubmed: 28288138
pmcid: 5509481
doi: 10.1038/onc.2017.47
Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004;5:163–75.
pubmed: 14998492
pmcid: 4217165
doi: 10.1016/S1535-6108(04)00020-0
Yin L, Kharbanda S, Kufe D. Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival response to hypoxia. J Biol Chem. 2007;282:257–66.
pubmed: 17102128
doi: 10.1074/jbc.M610156200
Bartsch R, Singer CF, Pfeiler G, Hubalek M, Stoeger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, et al. Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. Br J Cancer. 2021;124:1795–802.
pubmed: 33762716
pmcid: 8144560
doi: 10.1038/s41416-021-01284-2
Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stoger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, et al. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). Eur J Cancer. 2020;132:43–52.
pubmed: 32325419
doi: 10.1016/j.ejca.2020.03.018
Wimmer K, Sachet M, Ramos C, Frantal S, Birnleitner H, Brostjan C, Exner R, Filipits M, Bago-Horvath Z, Rudas M, et al. Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients. J Exp Clin Cancer Res. 2023;42:300.
pubmed: 37957750
pmcid: 10644559
doi: 10.1186/s13046-023-02876-x
Dubsky PC, Singer CF, Egle D, Wette V, Petru E, Balic M, Pichler A, Greil R, Petzer AL, Bago-Horvath Z, et al. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. Eur J Cancer. 2020;134:99–106.
pubmed: 32502940
doi: 10.1016/j.ejca.2020.04.020
Leong CF, Raudhawati O, Cheong SK, Sivagengei K, Noor Hamidah H. Epithelial membrane antigen (EMA) or MUC1 expression in monocytes and monoblasts. Pathology. 2003;35:422–7.
pubmed: 14555387
doi: 10.1080/00313020310001602576
Beatson R, Graham R, Grundland Freile F, Cozzetto D, Kannambath S, Pfeifer E, Woodman N, Owen J, Nuamah R, Mandel U, et al. Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype. Commun Biol. 2020;3:644.
pubmed: 33149188
pmcid: 7642421
doi: 10.1038/s42003-020-01359-5
Monti P, Leone BE, Zerbi A, Balzano G, Cainarca S, Sordi V, Pontillo M, Mercalli A, Di Carlo V, Allavena P, Piemonti L. Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J Immunol. 2004;172:7341–9.
pubmed: 15187110
doi: 10.4049/jimmunol.172.12.7341
Härkönen PL, Väänänen HK. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann N Y Acad Sci. 2006;1089:218–27.
pubmed: 17261769
doi: 10.1196/annals.1386.045
Pioli PA, Jensen AL, Weaver LK, Amiel E, Shen Z, Shen L, Wira CR, Guyre PM. Estradiol attenuates lipopolysaccharide-induced CXC chemokine ligand 8 production by human peripheral blood monocytes. J Immunol. 2007;179:6284–90.
pubmed: 17947704
doi: 10.4049/jimmunol.179.9.6284
Polan ML, Loukides J, Nelson P, Carding S, Diamond M, Walsh A, Bottomly K. Progesterone and estradiol modulate interleukin-1 beta messenger ribonucleic acid levels in cultured human peripheral monocytes. J Clin Endocrinol Metab. 1989;69:1200–6.
pubmed: 2584355
doi: 10.1210/jcem-69-6-1200
Souza C, Barbosa CD, Coelho H, Santos Júnior MN, Barbosa EN, Queiroz ÉC, Teles MF, Dos Santos DC, Bittencourt RS, Soares TJ, et al. Effects of 17β-Estradiol on Monocyte/Macrophage response to Staphylococcus aureus: an in Vitro Study. Front Cell Infect Microbiol. 2021;11:701391.
pubmed: 34336722
pmcid: 8317603
doi: 10.3389/fcimb.2021.701391
Adam O, Hagel M, Theobald K, Böhm M, Laufs U. Inhibitory effect of estrogen on Rac1-expression in monocytes. Biochem Biophys Res Commun. 2009;386:45–9.
pubmed: 19497305
doi: 10.1016/j.bbrc.2009.05.126
Friedrich EB, Clever YP, Wassmann S, Hess C, Nickenig G. 17Beta-estradiol inhibits monocyte adhesion via down-regulation of Rac1 GTPase. J Mol Cell Cardiol. 2006;40:87–95.
pubmed: 16332375
doi: 10.1016/j.yjmcc.2005.10.007
Yamada K, Hayashi T, Kuzuya M, Naito M, Asai K, Iguchi A. Physiological concentration of 17 beta-estradiol inhibits chemotaxis of human monocytes in response to monocyte chemotactic protein 1. Artery. 1996;22:24–35.
pubmed: 8781708
Mor G, Sapi E, Abrahams VM, Rutherford T, Song J, Hao XY, Muzaffar S, Kohen F. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J Immunol. 2003;170:114–22.
pubmed: 12496390
doi: 10.4049/jimmunol.170.1.114
Thongngarm T, Jenkins JK, Ndebele K, McMurray RW. Estrogen and progesterone modulate monocyte cell cycle progression and apoptosis. Am J Reprod Immunol. 2003;49:129–38.
pubmed: 12797519
doi: 10.1034/j.1600-0897.2003.00015.x
Iyer V, Klebba I, McCready J, Arendt LM, Betancur-Boissel M, Wu MF, Zhang X, Lewis MT, Kuperwasser C. Estrogen promotes ER-negative tumor growth and angiogenesis through mobilization of bone marrow-derived monocytes. Cancer Res. 2012;72:2705–13.
pubmed: 22467173
doi: 10.1158/0008-5472.CAN-11-3287
Ziegler-Heitbrock HW. Definition of human blood monocytes. J Leukoc Biol. 2000;67:603–6.
pubmed: 10810998
doi: 10.1002/jlb.67.5.603
Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019;106:309–22.
pubmed: 30776148
doi: 10.1002/JLB.4RI0818-311R
Schauer D, Starlinger P, Alidzanovic L, Zajc P, Maier T, Feldman A, Padickakudy R, Buchberger E, Elleder V, Spittler A, et al. Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response. Oncoimmunology. 2016;5:e1160185.
pubmed: 27471631
pmcid: 4938316
doi: 10.1080/2162402X.2016.1160185
Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, Kourilsky P, Wong SC. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011;118:e16–31.
pubmed: 21653326
doi: 10.1182/blood-2010-12-326355
Zawada AM, Rogacev KS, Rotter B, Winter P, Marell RR, Fliser D, Heine GH. SuperSAGE evidence for CD14 + + CD16 + monocytes as a third monocyte subset. Blood. 2011;118:e50–61.
pubmed: 21803849
doi: 10.1182/blood-2011-01-326827
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–22.
pubmed: 17785706
doi: 10.1200/JCO.2007.10.6823
Fendl B, Weiss R, Eichhorn T, Spittler A, Fischer MB, Weber V. Storage of human whole blood, but not isolated monocytes, preserves the distribution of monocyte subsets. Biochem Biophys Res Commun. 2019;517:709–14.
pubmed: 31387744
doi: 10.1016/j.bbrc.2019.07.120
Zagrapan B, Eilenberg W, Prausmueller S, Nawrozi P, Muench K, Hetzer S, Elleder V, Rajic R, Juster F, Martelanz L, et al. A Novel Diagnostic and Prognostic score for abdominal aortic aneurysms based on D-Dimer and a comprehensive analysis of myeloid cell parameters. Thromb Haemost. 2019;119:807–20.
pubmed: 30822810
doi: 10.1055/s-0039-1679939
Fadhil M, Abdul-Rasheed O, Al-Naqqash M. Clinical value of peripheral blood M2/M1 like monocyte ratio in the diagnosis of breast cancer and the differentiation between benign and malignant breast tumors. Acta Biochim Pol. 2019;66:437–43.
pubmed: 31794652
Feng AL, Zhu JK, Sun JT, Yang MX, Neckenig MR, Wang XW, Shao QQ, Song BF, Yang QF, Kong BH, Qu X. CD16 + monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis. Clin Exp Immunol. 2011;164:57–65.
pubmed: 21361908
pmcid: 3074217
doi: 10.1111/j.1365-2249.2011.04321.x
Foulds GA, Vadakekolathu J, Abdel-Fatah TMA, Nagarajan D, Reeder S, Johnson C, Hood S, Moseley PM, Chan SYT, Pockley AG, et al. Immune-phenotyping and transcriptomic profiling of Peripheral Blood mononuclear cells from patients with breast Cancer: identification of a 3 gene signature which predicts relapse of Triple negative breast Cancer. Front Immunol. 2018;9:2028.
pubmed: 30254632
pmcid: 6141692
doi: 10.3389/fimmu.2018.02028
Larsson AM, Nordström O, Johansson A, Rydén L, Leandersson K, Bergenfelz C. Peripheral blood mononuclear cell populations correlate with outcome in patients with metastatic breast Cancer. Cells. 2022;11:1639.
Verronèse E, Delgado A, Valladeau-Guilemond J, Garin G, Guillemaut S, Tredan O, Ray-Coquard I, Bachelot T, N’Kodia A, Bardin-Dit-Courageot C, et al. Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. Oncoimmunology. 2016;5:e1100791.
pubmed: 27141361
doi: 10.1080/2162402X.2015.1100791
Hanamura T, Kitano S, Kagamu H, Yamashita M, Terao M, Tsuda B, Okamura T, Kumaki N, Hozumi K, Harada N, et al. Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression. Sci Rep. 2022;12:8098.
pubmed: 35577913
pmcid: 9110375
doi: 10.1038/s41598-022-11578-x
Kiss M, Caro AA, Raes G, Laoui D. Systemic reprogramming of monocytes in Cancer. Front Oncol. 2020;10:1399.
pubmed: 33042791
pmcid: 7528630
doi: 10.3389/fonc.2020.01399
Kramer PR, Kramer SF, Guan G. 17 beta-estradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocyte-derived macrophages. Arthritis Rheum. 2004;50:1967–75.
pubmed: 15188374
doi: 10.1002/art.20309
Kramer PR, Winger V, Kramer SF. 17beta-Estradiol utilizes the estrogen receptor to regulate CD16 expression in monocytes. Mol Cell Endocrinol. 2007;279:16–25.
pubmed: 17923257
pmcid: 2128779
doi: 10.1016/j.mce.2007.08.014
Borras M, Hardy L, Lempereur F, el Khissiin AH, Legros N, Gol-Winkler R, Leclercq G. Estradiol-induced down-regulation of estrogen receptor. Effect of various modulators of protein synthesis and expression. J Steroid Biochem Mol Biol. 1994;48:325–36.
pubmed: 8142311
doi: 10.1016/0960-0760(94)90072-8
Phiel KL, Henderson RA, Adelman SJ, Elloso MM. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett. 2005;97:107–13.
pubmed: 15626482
doi: 10.1016/j.imlet.2004.10.007
Murphy AJ, Guyre PM, Wira CR, Pioli PA. Estradiol regulates expression of estrogen receptor ERalpha46 in human macrophages. PLoS ONE. 2009;4:e5539.
pubmed: 19440537
pmcid: 2678254
doi: 10.1371/journal.pone.0005539
Pelekanou V, Kampa M, Kiagiadaki F, Deli A, Theodoropoulos P, Agrogiannis G, Patsouris E, Tsapis A, Castanas E, Notas G. Estrogen anti-inflammatory activity on human monocytes is mediated through cross-talk between estrogen receptor ERα36 and GPR30/GPER1. J Leukoc Biol. 2016;99:333–47.
pubmed: 26394816
doi: 10.1189/jlb.3A0914-430RR
Valdés-Ferrada J, Muñoz-Durango N, Pérez-Sepulveda A, Muñiz S, Coronado-Arrázola I, Acevedo F, Soto JA, Bueno SM, Sánchez C, Kalergis AM. Peripheral blood classical monocytes and plasma interleukin 10 are Associated to Neoadjuvant Chemotherapy response in breast Cancer patients. Front Immunol. 2020;11:1413.
pubmed: 32733470
pmcid: 7363840
doi: 10.3389/fimmu.2020.01413
Karihtala P, Leivonen SK, Puistola U, Urpilainen E, Jaaskelainen A, Leppa S, Jukkola A. Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival. Breast Cancer Res. 2024;26:61.
pubmed: 38594742
pmcid: 11005292
doi: 10.1186/s13058-024-01812-x
Singer CF, Filipits M, Jahn SW, Abete L, Jakesz R, Greil R, Bauernhofer T, Kwasny W, Seifert M, Fitzal F, et al. Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer. Breast. 2019;46:101–7.
pubmed: 31132475
doi: 10.1016/j.breast.2019.05.007
Little AC, Pathanjeli P, Wu Z, Bao L, Goo LE, Yates JA, Oliver CR, Soellner MB, Merajver SD. IL-4/IL-13 stimulated macrophages enhance breast Cancer Invasion Via Rho-GTPase regulation of synergistic VEGF/CCL-18 signaling. Front Oncol. 2019;9:456.
pubmed: 31214501
pmcid: 6554436
doi: 10.3389/fonc.2019.00456
Sheng D, Ma W, Zhang R, Zhou L, Deng Q, Tu J, et al. Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization. J Immunother Cancer. 2022;10:e003793.
Hsu YH, Hsing CH, Li CF, Chan CH, Chang MC, Yan JJ, Chang MS. Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J Immunol. 2012;188:1981–91.
pubmed: 22238453
doi: 10.4049/jimmunol.1102843
Felcher CM, Bogni ES, Kordon EC. IL-6 Cytokine Family: a putative target for breast Cancer Prevention and Treatment. Int J Mol Sci. 2022;23:1809.
Todorovic-Rakovic N, Milovanovic J. Interleukin-8 in breast cancer progression. J Interferon Cytokine Res. 2013;33:563–70.
pubmed: 23697558
pmcid: 3793647
doi: 10.1089/jir.2013.0023